Combination Therapies: Opportunities for Improved CAR-T Cell Therapy?
Chimeric antigen receptor (CAR) cell therapy offers hope where other cancer therapies have failed. However,…
Chimeric antigen receptor (CAR) cell therapy offers hope where other cancer therapies have failed. However,…
Confidence in gene-edited T cell therapies from donor cells has faltered as Allogene Therapeutics paused…
CAR-T therapy has been hailed as a cure for cancer, but what really is this…
Update (01/02/2019): MorphoSys has agreed to end its long-running legal battle with Genmab and Janssen, after…
Update (14/01/2019): An anonymous French company on Euronext has made an offer to take over…
Janssen will discontinue a Phase I study testing Danish biotech Genmab's blood cancer blockbuster daratumumab…
Our very own red blood cells could soon become a treatment for some of the…
Celyad has reported clinical results showing the first time a patient has fully recovered from…
This week, we're in Barcelona, Spain, to visit Leukos Biotech, whose goal is to develop…
Genmab's leukemia drug will be available around the world through compassionate use programs, while it will…
Now that we've got the bad news out of the way, we're here to spread…
Data presented at ASH 2017 shows that Servier and Pfizer's UCART19, an allogeneic CAR-T therapy…